Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing increases in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction price of 1,470.26 pence per share.
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The filing exclusively details the re-investment of dividends paid on July 5, 2012, into ordinary shares by various executives on July 11, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Directors and senior managers increased their shareholdings on July 11, 2012, via dividend re-investment.
- The transaction price was 1,470.26 pence per share.
- Notable participants include Sir Andrew Witty (1,476.467 shares) and Dr M M Slaoui (227.382 shares).
- The Company Secretary, V A Whyte, reported zero new shares acquired (0.008 shares) in this specific transaction.
- This filing does not contain quarterly or annual financial performance data.